# Progress Note 02 — Focused Visit (Follow-up)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Muhammad Ali (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-BX001-SYN-TD
- Date: 1996-03-10
- Fictional facility: St. Posthumous Health Center
- Fictional author: Celeste Moreau, MD
- Calendar frame: true historical dates (modern content is anachronistic)

> True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

- Visit type: Focused Visit (Follow-up)

## Chief complaint

Four-week Parkinson's disease follow-up, seen the same day by movement disorders neurology. **S**

## History of present illness

Mr. Ali is a 54-year-old man with young-onset Parkinson's disease, diagnosed twelve years ago, who returns four weeks after his first visit and is seen by movement disorders neurology on the same day. Slowness of movement is still his main limitation: buttoning, handwriting, and getting out of low chairs take him longer, and he feels the slowness most in the late morning and late afternoon. The right-hand tremor is mild and settles when he uses the hand. People still have trouble hearing him in a crowd. He takes carbidopa-levodopa 25/100 mg one tablet three times a day, often with meals, and has noticed no wearing-off before doses, no involuntary movements, and no lightheadedness on standing. He has had no falls or near falls. He sleeps well, has no dream enactment, and has no hallucinations or new urges to gamble, shop, or eat. **S**

| Element | Detail |
|---|---|
| Motor symptoms | Slowness the main limitation; mild right-hand rest tremor; no freezing |
| Motor complications | No wearing-off or dyskinesia |
| Falls | None |
| Speech | Soft voice; hard to hear in crowds |
| Non-motor | No lightheadedness, hallucinations, impulse-control problems, constipation, or sleep problems |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Cardiovascular | Negative | No lightheadedness on standing or fainting |
| Gastrointestinal | Negative | No nausea, constipation, or trouble swallowing |
| Neurological | Positive | Slowness of movement and mild right-hand tremor; no freezing or involuntary movements |
| Psychiatric | Negative | Mood good; no hallucinations or impulse-control problems |
| Ears, nose, mouth, and throat | Positive | Soft voice, hard to hear in noisy places; no drooling |

5 systems reviewed. **S**

## Current medications

- Carbidopa-levodopa 25/100 mg oral tablet, one and a half tablets by mouth three times daily, 30 minutes before meals **S**

## Allergies

- No known allergy **S**

## Objective

BP 126/78 mmHg; pulse 70 bpm; respirations 14/min; temperature 36.6 °C; oxygen saturation 98% on room air; weight 102 kg; BMI 28 kg/m². All vital signs are synthetic.

No condition-specific results recorded.

## Physical examination

| System | Finding |
|---|---|
| General | Alert, humorous, and engaged; reduced facial expression |
| Cardiovascular | Regular rhythm at 70 per minute. Blood pressure 128/80 mmHg after 5 minutes supine and 122/78 mmHg after 3 minutes standing, without symptoms; no orthostatic hypotension |
| Neurological | In the on state about two hours after a dose: MDS-UPDRS Part III 30, Hoehn and Yahr stage 2.5. Bilateral bradykinesia and rigidity, worse on the right; mild right-hand rest tremor; soft, monotone speech; no dyskinesia |
| Gait | Short steps with reduced arm swing; recovers unaided after three steps on the pull test; Timed Up and Go 13 seconds |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Parkinson's disease, Hoehn and Yahr stage 2.5** (G20.A1). Neurology confirms clinically established Parkinson's disease by the MDS criteria. Bradykinesia limits daily tasks on a modest levodopa dose, with no motor fluctuations or dyskinesia. No orthostatic hypotension. No falls, but short steps and a slowed pull-test recovery mean his fall risk is rising. **S**
   - Increase carbidopa-levodopa to one and a half 25/100 mg tablets (levodopa 150 mg) three times daily, 30 minutes before meals, as neurology advises.
   - Spread protein through the day rather than taking doses with a large protein meal.
   - Physical therapy for gait, balance, and a home exercise program of at least 150 minutes a week.
   - Supine and standing blood pressure at the three-month review, after the dose increase.
2. **Hypokinetic dysarthria with soft speech** (R47.1). Soft, monotone speech, with intelligibility reduced in noise. **S**
   - Four-week intensive speech therapy course (LSVT LOUD), starting next week.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Examination | MDS-UPDRS Parts III and IV and Hoehn and Yahr stage | Every visit | Completed today | Part III 30 in the on state; Hoehn and Yahr 2.5; Part IV: no dyskinesia, wearing-off, or on-off |
| Examination | Orthostatic blood pressure, supine and after 3 minutes standing | Every visit while on dopaminergic treatment | Completed today | 128/80 mmHg supine and 122/78 mmHg at 3 minutes standing; no orthostatic hypotension |
| Medication safety | Dopaminergic regimen review for wearing-off, dyskinesia, and on-off | Every visit | Completed today | No motor complications; bradykinesia limits daily tasks, so levodopa is increased to 150 mg three times daily before meals |
| Medication safety | Avoidance of dopamine-blocking drugs | Every visit | Completed today | No antipsychotic, metoclopramide, or prochlorperazine; ondansetron is the antiemetic of choice if one is ever needed |
| Medication safety | Medication side effects and adherence | Every visit | Completed today | No nausea or sleepiness; no missed doses, though doses are often taken with meals |
| Examination | Fall query and fall-risk assessment (Timed Up and Go, pull test) | Every visit | Completed today | No falls or near falls; Timed Up and Go 13 seconds; recovers after three steps on the pull test |
| Survey | Psychotic symptoms (hallucinations, delusions) | Every visit | Completed today | None |
| Survey | Impulse-control screen (QUIP-RS) | Every visit; mandatory on a dopamine agonist | Completed today | Negative; not on a dopamine agonist |
| Self-management | Exercise counseling: aerobic, resistance, and balance, at least 150 minutes a week | Every visit | Completed today | Walks 30 minutes most days; physical therapy will add balance and strength work toward 150 minutes a week |
| Self-management | Advance care planning and goals of care | At diagnosis and at least yearly | Due | Planned for the preventive visit in the autumn |
| Examination | Diagnosis review against the MDS clinical diagnostic criteria | Yearly | Completed today | Movement disorders neurology confirms clinically established Parkinson's disease: bradykinesia with rest tremor and rigidity, a clear response to levodopa, and no red flags |
| Survey | Cognitive screen (MoCA) | At least yearly | Up to date | MoCA 27 of 30 four weeks ago |
| Survey | Depression, anxiety, and apathy (PHQ-9) | At least yearly | Up to date | PHQ-9 3 four weeks ago |
| Survey | Sleep: REM sleep behavior disorder questionnaire, Epworth Sleepiness Scale, insomnia, restless legs | At least yearly | Up to date | Negative REM sleep behavior disorder screen and Epworth score 6 four weeks ago |
| Survey | Autonomic symptoms: constipation, urinary, sexual, sweating, drooling | At least yearly | Up to date | No autonomic symptoms four weeks ago |
| Survey | Swallowing screen (EAT-10) | At least yearly | Up to date | EAT-10 score 2 four weeks ago, below the threshold of 3 |
| Examination | Speech and voice loudness | Yearly; speech therapy for speech change | Referred | Soft, monotone speech; four-week LSVT LOUD course starts next week |
| Referral | Physical, occupational, and speech therapy | At diagnosis, then reassessed yearly | Referred | Physical therapy for gait and balance and speech therapy arranged; occupational therapy not needed now because he is independent in daily activities |
| Referral | Movement disorders neurology consultation | At diagnosis, then yearly or with a change | Completed today | Seen today for diagnosis review, levodopa adjustment, and rehabilitation planning |
| Laboratory | Genetic testing with counseling | Once, offered to every person with Parkinson's disease | Due | Offered by neurology today with counseling; he will decide at the yearly neurology review |
| Examination | Dental and oral examination | Every 6 months | Due | No dental visit on record; to be arranged |
| Examination | Driving safety | Yearly or with a motor or cognitive change | Up to date | Drives short local trips in daylight; MoCA 27 and no daytime sleepiness four weeks ago; review yearly or with any change |
| Self-management | Vaccination status (influenza, pneumococcal, zoster, COVID-19, Tdap) | Yearly, per the CDC schedule | Due | Influenza vaccine given last autumn; pneumococcal, zoster, COVID-19, and Tdap to be reviewed at the preventive visit |
| Laboratory | Routine laboratory monitoring | Not required for Parkinson's disease surveillance | Not indicated | The CMID monograph calls for no routine laboratory tests; baseline blood count, chemistry, vitamin B12, and TSH were normal at the first visit |
| Imaging | Brain MRI | If atypical parkinsonism features appear | Not indicated | No atypical features; neurology agrees no imaging is needed |
| Imaging | Polysomnography for REM sleep behavior disorder | If REM sleep behavior disorder treatment is considered | Not indicated | No dream enactment |
| Medication safety | AGS Beers Criteria medication review | Yearly from age 65 | Not indicated | He is 54 |
| Examination | Deep brain stimulation programming review | Every 6 to 12 months after implantation | Not indicated | No deep brain stimulator |

## Goal progress

- Less slowness of movement after a levodopa adjustment, without dyskinesia or orthostatic hypotension, by the three-month review. In progress; target 1996-06-09. **S**
- Complete a four-week intensive speech therapy course and keep up daily voice practice. In progress; target 1996-06-09. **S**
- No falls through the six-month review, with at least 150 minutes a week of exercise including balance work. In progress; target 1996-09-08. **S**
- Name a health care agent and record his goals of care by the preventive visit. In progress; target 1996-10-06. **S**

## Medication changes

- Stopped: Carbidopa-levodopa 25/100 mg oral tablet, one tablet by mouth three times daily **S**
- Started: Carbidopa-levodopa 25/100 mg oral tablet, one and a half tablets by mouth three times daily, 30 minutes before meals **S**

## Guideline basis

- Dopaminergic Therapy for Motor Symptoms in Early Parkinson Disease Practice Guideline Summary: A Report of the AAN Guideline Subcommittee (2021), American Academy of Neurology (Neurology)
- MDS clinical diagnostic criteria for Parkinson's disease (2015), International Parkinson and Movement Disorder Society (Movement Disorders)
- The recommendations of a consensus panel for the screening, diagnosis, and treatment of neurogenic orthostatic hypotension and associated supine hypertension (2017), American Autonomic Society and National Parkinson Foundation (Journal of Neurology)
- CMID: Clinical Monitoring Intelligence Database, Parkinson's disease monograph (2026), Aether Forge

## Follow-up

- Three-month Parkinson's disease review, with supine and standing blood pressure after the levodopa increase. Speech therapy starts next week and physical therapy within two weeks. **S**
- Next scheduled visit 1996-06-09: three-month Parkinson's disease review after the levodopa increase and speech therapy. **S**
